{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260612246187/en/FDA-Approves-KEYTRUDA%C2%AE-pembrolizumab-and-KEYTRUDA-QLEX%E2%84%A2-pembrolizumab-and-berahyaluronidase-alfa-pmph-Each-With-WELIREG%C2%AE-belzutifan-for-Adjuvant-Treatment-of-Certain-Patients-With-Clear-Cell-Renal-Cell-Carcinoma-ccRCC", "message": "News view counter 796895 successfully enlarged"}